<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6639">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988103</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSOR-011</org_study_id>
    <nct_id>NCT01988103</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis</brief_title>
  <official_title>A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the clinical effectiveness and safety of two orally administered doses
      of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type
      psoriasis.

      Apremilast (CC-10004) is a new oral agent that is under clinical development for the
      treatment of inflammatory autoimmune disorders such as psoriasis, psoriatic arthritis,
      ankylosing spondylitis, rheumatoid arthritis, and Behçet disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study of the
      efficacy and safety of apremilast 20 mg twice a day (BID), apremilast 30 mg BID, and placebo
      in Japanese subjects with moderate to severe plaque psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index-75 (PASI-75).</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects with either apremilast 20 mg BID, apremilast 30 BID or placebo who achieve at least a 75% reduction from baseline in PASI (PASI-75)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subject with a Static Physician's Global Assessment (sPGA) score of clear (0) or almost clear (1)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from baseline in the psoriasis affected Body Surface Area (BSA %)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in the PASI score</measure>
    <time_frame>From Baseline at Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve PASI-50</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Pruritus Visual Analogue Scale (VAS)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Dermatology Life Quality Index  (DLQI) total score</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mental Component Summary (MCS) score of SF-36</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Weeks 16 and 68</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Type, frequency, severity, and relationship of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For subjects with a diagnosis of psoriatic arthritis at screening: Proportion of subjects who achieve an American College of Rheumatology criteria for a 20% improvement (ACR 20)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For subjects with a diagnosis of psoriatic arthritis at screening: Change from baseline in Psoriatic Arthritis Pain VAS</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For subjects with a diagnosis of psoriatic arthritis at screening: Change from baseline in physical function (Health Assessment Questionnaire Disability Index [HAQ-DI])</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum observed concentration in plasma, unit = ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time of maximum plasma concentration, unit = h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC0-8 and AUC0-τ</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve from time 0 to 8 hours and from 0 to 12 hours after a dose of apremilast, unit = ng•h/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t1/2</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Elimination half life unit = h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CLss/F</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Apparent systemic clearance at steady state, unit = L/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vss/F</measure>
    <time_frame>Week 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Apparent volume of distribution at steady state unit = L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics (sparse sampling) - CL/F</measure>
    <time_frame>Weeks 8-24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug Clearance, unit = L/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics (sparse sampling) - Vc/F</measure>
    <time_frame>Week 8-24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Volume of Distribution, unit = L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics (sparse sampling) - KA</measure>
    <time_frame>Week 8-24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Absorption rate constant, unit = 1/h</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Psoriasis;</condition>
  <condition>Psoriatic Arthritis;</condition>
  <condition>Psoriasis Arthropatica</condition>
  <arm_group>
    <arm_group_label>Apremilast 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Apremilast 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>20 mg tablet twice a day for 68 weeks</description>
    <arm_group_label>Apremilast 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>30 mg tablet twice a day for 68 weeks</description>
    <arm_group_label>Apremilast 30mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice a day for 16 weeks followed by apremilast 20 mg tablet twice a day for 52 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice a day for 16 weeks followed by apremilast 30 mg tablet twice a day for 52 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Japanese subjects greater than or equal to 20 years of age.

          -  Diagnosis of chronic, stable plaque psoriasis for at least 6 months prior to
             screening as defined by:  PASI score ≥ 12 and BSA ≥ 10%.

          -  Psoriasis which is considered inappropriate for topical therapy (based on severity of
             disease and extent of affected area) or has not been adequately controlled or treated
             by topical therapy in spite of at least 4 weeks of prior therapy with at least one
             topical medication for psoriasis or per label.

          -  In otherwise good health based on medical history, physical examination, 12-lead ECG,
             serum chemistry, hematology, immunology, and urinalysis.

        Exclusion Criteria:

          -  Other than psoriasis, history of any clinically significant and uncontrolled systemic
             diseases; any condition, including the presence of laboratory abnormalities, which
             would place the subject at unacceptable risk or confound the ability to interpret the
             data in the study.

        Prior medical history of suicide attempt or major psychiatric illness requiring
        hospitalization within the last 3 years

          -  Pregnant or breastfeeding.

          -  History of or ongoing chronic or recurrent infectious disease.

          -  Active tuberculosis (TB) or a history of incompletely treated TB.

          -  Clinically significant abnormality on 12-lead ECG or on chest radiograph at
             screening.

          -  History of human immunodeficiency virus (HIV) infection or have congenital or
             acquired immunodeficiencies (eg, Common Variable Immunodeficiency).

          -  Hepatitis B surface antigen or hepatitis B core antibody positive at screening;
             positive for antibodies to hepatitis C at screening.

          -  Malignancy or history of malignancy, except for treated (ie, cured) basal cell or
             squamous cell in situ skin carcinomas or treated (ie, cured) cervical intraepithelial
             neoplasia (CIN) or carcinoma in situ of the cervix with no evidence of recurrence
             within previous 5 years.

          -  Psoriasis flare within 4 weeks of screening.

          -  Topical therapy within 2 weeks prior to randomization or systemic therapy for
             psoriasis or psoriatic arthritis within 4 weeks prior to randomization.

          -  Use of etretinate within 2 years prior to randomization for females of child bearing
             potential (FCBP) or within 6 months for males, and within 4 weeks prior to
             randomization for non-FCBP.

          -  Use of phototherapy (ie, UVB, PUVA) within 4 weeks prior to randomization or
             prolonged sun exposure or use of tanning booths or other ultraviolet light sources.

          -  Use of adalimumab, etanercept, certolizumab pegol, abatacept, tocilizumab, golimumab
             or infliximab within 12 weeks prior to randomization; use of ustekinumab, alefacept
             or briakinumab within 24 weeks prior to randomization.

          -  Any investigational drug within 4 weeks prior to randomization.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Khanskaya, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dale McElveen, MBA</last_name>
    <phone>732-652-6699</phone>
    <email>dmcelveen@celgene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allan Maroli, Ph.D.</last_name>
    <phone>732-652-6143</phone>
    <email>amaroli@celgene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HATAMOTO Derma Clinic</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>815-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ekihigashi Hifuka Clinic</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>812-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tomoko Matsuda Dermatological Clinic</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>819-0167</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tsutsui Clinic Dermatology &amp; Plastic Surgery</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>813-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yano Hifuka Hinyokika Clini</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>814-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TASHIRO Dermatological Clinic</name>
      <address>
        <city>Iizuka-shi</city>
        <state>Fukuoka</state>
        <zip>820-0040</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Matsuda Dermatology Clinic For Skin, Hair, Nail Diseases</name>
      <address>
        <city>Itoshima-shi</city>
        <state>Fukuoka</state>
        <zip>819-1116</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okubo Skin Care and Clinic</name>
      <address>
        <city>Itoshima-shi</city>
        <state>Fukuoka</state>
        <zip>819-1108</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu Kosei Nenkin Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>806-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kitakyushu Municipal Medical Center</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyusyu Rosai Hospital</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>800-0296</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Matsuo Clinic</name>
      <address>
        <city>Nishi-Ku</city>
        <state>Fukuoka</state>
        <zip>819-0373</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yame General Hospital</name>
      <address>
        <city>Yame</city>
        <state>Fukuoka</state>
        <zip>834-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kokubu Medical Office Abashiri Dermatology Clinic</name>
      <address>
        <city>Abashiri-shi</city>
        <state>Hokkaido</state>
        <zip>093-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asanuma Dermatology Clinic</name>
      <address>
        <city>Chitose-shi</city>
        <state>Hokkaido</state>
        <zip>066-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chitose Dermatology Plastic Surgery Clinic</name>
      <address>
        <city>Chitose-shi</city>
        <state>Hokkaido</state>
        <zip>066-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kokubu Dermatology</name>
      <address>
        <city>Kitami-shi</city>
        <state>Hokkaido</state>
        <zip>090-0832</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapporo Skin Clinic</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuzumi Dermatology Clinic</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>062-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center</name>
      <address>
        <city>Kobe City</city>
        <state>Hyogo</state>
        <zip>653-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hitachi General Hospital</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <zip>317-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Ibaraki Medical Center</name>
      <address>
        <city>Inashiki-gun</city>
        <state>Ibaraki</state>
        <zip>300-0395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teikyo University School of Medicine University Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>213-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanto Rosai Hospital</name>
      <address>
        <city>Kawasaki City</city>
        <state>Kanagawa</state>
        <zip>211-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kawasaki Saiwai Clinic</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>212-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sagamihara National Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>213-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen's Square Medical Facilities</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>220-6208</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nomura Dermatology Clinic</name>
      <address>
        <city>Yokohoma City</city>
        <state>Kanagawa</state>
        <zip>221-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokosuka Kyosai Hospital</name>
      <address>
        <city>Yokosuka</city>
        <state>Kanagawa</state>
        <zip>238-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kumamoto Shinto General Hospital</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>862-0975</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kosumi lin</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>860-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kume Derma Clinic</name>
      <address>
        <city>Sakai-Shi</city>
        <state>Osaka</state>
        <zip>593-8324</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SANRUI Dermatology</name>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama</state>
        <zip>330-0854</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sugai Dermatologist Park Side Clinic</name>
      <address>
        <city>Utsunomiya-shi</city>
        <state>Tochigi</state>
        <zip>321-0954</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kayaba Dermatology Clinic</name>
      <address>
        <city>Cyu-o-ku</city>
        <state>Tokyo</state>
        <zip>103-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokai University School of Medicine</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inagi Municipal Hospital</name>
      <address>
        <city>Inagi</city>
        <state>Tokyo</state>
        <zip>206-2801</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TSUTSUMI Clinic</name>
      <address>
        <city>Itabasi‐Ku</city>
        <state>Tokyo</state>
        <zip>174-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Koto Hospital</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>136-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maruyama Dermatology Clinic</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>136-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OIZUMI HANAWA Clinic</name>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <zip>178-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NAOKO Dermatology Clinic</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>158-0097</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kitahara Dermatology Clinic</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>158-0094</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mita Dermatology Clinic</name>
      <address>
        <city>Shiba Minato-k</city>
        <state>Tokyo</state>
        <zip>108-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjyuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taneda Dermatology Clinic</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <zip>166-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>190-8531</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shakaihoken Simonoseki Kosei Hospital</name>
      <address>
        <city>Shimonoseki-shi</city>
        <state>Yamaguchi</state>
        <zip>750-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Matsuo Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>719-0373</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMC Nishiumeda Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Center Clinic</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>May 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis; Psoriatic Arthritis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
